SCHEMBL16786277

SCHEMBL16786277

CCOC(=O)C(O[Si](C)(C)C(C)(C)C)P(C)(C)=O

nearest known ligand 0.33

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 1/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2C19 P33261 1/20 0.33
POLB P06746 1/20 0.31
MAPT P10636 1/20 0.31
PKM P14618 1/20 0.31
ALDH1A1 P00352 2/20 0.30
CYP3A4 P08684 1/20 0.30
ALOX15 P16050 1/20 0.30
TSHR P16473 1/20 0.30
TDP1 Q9NUW8 1/20 0.30
CYP4F2 P78329 1/20 0.30
CYP4A11 Q02928 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21063453 0.84 ALDH1A1 (0.35) CYP2C19ALDH1A1CYP3A4ALOX15TSHR
SCHEMBL9575398 0.77 ALDH1A1 (0.36) POLBMAPTPKMALDH1A1ALOX15
SCHEMBL1578908 0.75 MMP8 (0.35) CYP2C19POLBALDH1A1CYP3A4ALOX15
SCHEMBL1578905 0.75 MMP8 (0.35) CYP2C19POLBALDH1A1CYP3A4ALOX15
SCHEMBL31054671 0.75 MMP8 (0.35) CYP2C19POLBALDH1A1CYP3A4ALOX15
SCHEMBL1828667 0.75 MMP8 (0.35) CYP2C19POLBALDH1A1CYP3A4ALOX15
SCHEMBL27915963 0.72 MMP8 (0.33) CYP2C19ALDH1A1CYP3A4ALOX15
SCHEMBL13573094 0.71 METAP2 (0.35) ALDH1A1
SCHEMBL13573093 0.71 MMP8 (0.33) ALDH1A1
SCHEMBL7595924 0.69 GAA (0.39) CYP2D6CYP2C9CYP2C19ALDH1A1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230192756-A1 NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF Sage Therapeutics, LLC 2023-06-22 US disclosed
US-20160022701-A1 NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF SAGE THERAPEUTICS INC (US) 2016-01-28 US disclosed
US-20150158903-A1 NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF SAGE THERAPEUTICS, INC. (US) 2015-06-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160022701-A1 NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF CYP21A2, CYP24A1, HSD17B2 CYP2D6 622/4885CYP2C9 1362/4885CYP2C19 406/4885
US-20230192756-A1 NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF CHRNB4, CHRNB3, MC2R CYP2D6 471/4885CYP2C9 843/4885CYP2C19 603/4885
US-20150158903-A1 NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF CHRNB4, CHRNB3, MC2R CYP2D6 471/4885CYP2C9 843/4885CYP2C19 603/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.